Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DBV Technologies S.A. - American Depositary Shares (NQ:DBVT)

15.99 -0.29 (-1.78%)
Streaming Delayed Price Updated: 2:08 PM EDT, Jun 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DBV Technologies S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces the Results of its 2026 Combined General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Combined General Meeting of June 3, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports First Quarter 2026 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in Upcoming March Investor Conferences
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion.... 
Via MarketMinute
Topics Intellectual Property
News headline image
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Which stocks are moving before the opening bell on Monday? ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
DBV Technologies Stock Soars 63% After Hours As Strong Results For Peanut Allergy Patch Clears Path For FDA Filing ↗
According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful.” 
Via Stocktwits
News headline image
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
From DBV Technologies S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.